<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096195</url>
  </required_header>
  <id_info>
    <org_study_id>3638</org_study_id>
    <nct_id>NCT05096195</nct_id>
  </id_info>
  <brief_title>PRevEnting FracturEs in Renal Disease - 1</brief_title>
  <acronym>PREFERRED-1</acronym>
  <official_title>Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic Medical Organization of Southwestern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Kidney Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREFERRED-1 is a pilot study for a large randomized, pragmatic, open-label,&#xD;
      comparative-effectiveness trial. The pilot will enroll at least 60 patients across 6&#xD;
      different hemodialysis centres in Ontario, Canada. Patients on outpatient maintenance&#xD;
      hemodialysis at high risk of fragility fracture will be randomized 1:1 to denosumab vs.&#xD;
      no-denosumab (i.e. usual care).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>3 months</time_frame>
    <description>Number or N (%) participants recruited within 3 months of trial approval in each centre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to study intervention</measure>
    <time_frame>15 months</time_frame>
    <description>N(%) participants randomized to the intervention receive &gt;90% of their scheduled denosumab injections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to usual care</measure>
    <time_frame>15 months</time_frame>
    <description>N(%) participants randomized to usual care who do not receive a prescription for denosumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related hypocalcemia as assessed by CTCAE v4.0</measure>
    <time_frame>15 months</time_frame>
    <description>N(%) with Grade 2: albumin-adjusted serum calcium &lt; 2.00 to 1.75 mmol/L; Grade 3 albumin-adjusted serum calcium &lt; 1.75 to 1.5 mmol/L; Grade 4: albumin-adjusted serum calcium &lt; 1.5 mmol/L at 1, 2, 3 and 4 weeks following denosumab injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum calcium</measure>
    <time_frame>15 months</time_frame>
    <description>Mean (standard deviation), change in corrected serum calcium between baseline and last followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change in serum calcium</measure>
    <time_frame>15 months</time_frame>
    <description>Median (interquartile range, IQR), change in corrected serum calcium between baseline and last followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in parathyroid hormone</measure>
    <time_frame>15 months</time_frame>
    <description>Mean (standard deviation) change in parathyroid hormone between baseline and last followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median change in parathyroid hormone</measure>
    <time_frame>15 months</time_frame>
    <description>Median (IQR) change in parathyroid hormone between baseline and last followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fragility fracture</measure>
    <time_frame>15 months</time_frame>
    <description>N (%) with hospital encounter for fragility fracture of the hip, vertebrae, humerus, wrist, or pelvis at 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant satisfaction with E-Platform</measure>
    <time_frame>15 months</time_frame>
    <description>Mean (SD) Likert scale score (1=not satisfied, 5=very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant satisfaction with E-Consent</measure>
    <time_frame>15 months</time_frame>
    <description>Mean (SD) Likert scale score (1=not satisfied, 5=very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant satisfaction with intervention</measure>
    <time_frame>15 months</time_frame>
    <description>Mean (SD) Likert scale score in those randomized to intervention (1=not satisfied, 5=very satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Dialysis; Complications</condition>
  <condition>Fragility Fracture</condition>
  <condition>Chronic Kidney Disease-Mineral and Bone Disorder</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 mg/ml [Prolia]</intervention_name>
    <description>Denosumab 60 mg (Prolia) every 6 months</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcium and vitamin D prophylaxis</intervention_name>
    <description>Per protocol adjustment of calcium dialysate and intravenous (IV) calcitriol and replacement of 25 hydroxyvitamin D (if indicated)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Monitoring of calcium and phosphate</intervention_name>
    <description>Serum calcium and phosphate for 4 weeks following each denosumab injection.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Treating nephrologist/nurse practitioner in the dialysis unit approves patient(s)&#xD;
             enrollment.&#xD;
&#xD;
          2. Age ≥40 years&#xD;
&#xD;
          3. Access to provincial drug benefits (i.e. Ontario Drug Benefits Program, Ontario&#xD;
             Disability Support Program)&#xD;
&#xD;
          4. Baseline albumin-corrected serum calcium ≥2.15 mmol/L, parathyroid hormone (PTH) 15-60&#xD;
             pmol/L, alkaline phosphatase (ALP) 80-120U/L.&#xD;
&#xD;
          5. High risk of fragility fracture defined by fracture history or World Health&#xD;
             Organization's Fracture Risk Assessment Tool&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Expected to recover kidney function, stop hemodialysis and pursue palliative care,&#xD;
             start IV bisphosphonates (i.e. pamidronate or zoledronic acid) for cancer, receive a&#xD;
             kidney transplant, or transfer to home or peritoneal dialysis within 12 months of&#xD;
             randomization (as assessed by a health professional).&#xD;
&#xD;
          2. Use of cinacalcet (Sensipar) within the last 3 months.&#xD;
&#xD;
          3. Use another osteoporosis medication including:&#xD;
&#xD;
             Alendronate (Fosavance or Fosamax) Risedronate (Actonel or Actonel DR) Raloxifene&#xD;
             (Evista) Oral or conjugated estrogen Topical, oral or injectable testosterone&#xD;
             (Androgel, Testim, Fortesta, Androderm, testosterone enanthate and testosterone&#xD;
             cypionate Teriparatide (Forteo) Romosozumab (Evenity) Calcitonin (Calcimar)&#xD;
&#xD;
          4. History of femur fracture attributed to osteoporosis medication use (i.e midshaft&#xD;
             femoral fracture or atypical femoral fracture)&#xD;
&#xD;
          5. Major dental surgery planned within the next 12 months (e.g. root canal).&#xD;
&#xD;
          6. Known allergy or intolerance to denosumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Kristin Clemens</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pilot</keyword>
  <keyword>Feasibility</keyword>
  <keyword>Registry-based trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

